This study is currently not recruiting participants.

A Randomized Phase II Trial of Erlotinib Cabozantinib or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC

Investigating Treatments for Stage IV Non-Small Cell Lung Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer.

Detailed description of study

This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lung Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effectiveness of different treatments for patients with stage IV non-small cell lung cancer. Non-small cell lung cancer is a type of lung cancer that grows and spreads more slowly than small cell lung cancer. The purpose of this study is to explore how well the investigational medication works alone or in combination as a second or third line therapy for this condition.

Participants in the study will receive either the investigational medication alone or in combination with another treatment. The study is randomized, meaning participants will be assigned by chance to different study arms to compare the outcomes of each treatment approach.

  • Who can participate: Participants must have stage IV non-small cell lung cancer, be receiving second or third line therapy, and meet specific age criteria.
  • Study details: Participants will be assigned to receive either the investigational medication alone or in combination with another treatment. The study is randomized to compare the effectiveness of each approach.
Updated on 19 Feb 2024. Study ID: 1310508461

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team